• Latest Opinion Piece

  Social Media: The Newest Frontier for Pharmacovigilance

  Social Media: The Newest Frontier for Pharmacovigilance

• 

  Opinion Piece

  AI Governance is becoming Pharma’s Next Big Compliance Challenge

• 

  Opinion Piece

  The Real Danger of Healthcare AI is not Hallucination; It’s How it Affects your Thinking

• 

  Opinion Piece

  Paraxel acquires Vitrana to boost drug safety automation

• 

  Opinion Piece

  ChatGPT for Clinicians: A New Frontier for AI in Healthcare

• 

  Opinion Piece

  AI and Digital Biomarkers Push Parkinson’s Trials into Real-World Monitoring

• 

  Opinion Piece

  The AI Model too Dangerous for the Public – Should we be Worried?

• 

  Opinion Piece

  AI Airlock is the Key to building a Regulatory Pathway for AI in UK Healthcare

• 

  Opinion Piece

  Multi-Target Drug Design Enters the AI Era

• 

  Opinion Piece

  How AI is Assisting Drug Label Analysis

• 

  Opinion Piece

  Using AI for Regulatory Compliance? Here’s what not to do

• 

  Opinion Piece

  The Disease that Fooled AI, then Fooled Science

• 

  Opinion Piece

  Reflections on DIA Europe 2026

• 

  Opinion Piece

  What I Learned at DIA Europe 2026 as a Pharmacovigilance Intern

• 

  Opinion Piece

  The Constraints of AI: Power, Scale and Sustainability

• 

  Opinion Piece

  End of Animal Testing? UK Regulators Pivot to AI

• 

  Opinion Piece

  AI in Clinical Trials is Moving Fast… but only if We Trust It

• 

  Opinion Piece

  DIA Europe 2026

• 

  Opinion Piece

  Why Humans Matter more than Ever in Pharmacovigilance: The Quiet Shift

• 

  Opinion Piece

  Synthetic Data: Safely Accelerating AI with Simulated Patients

• 

  Opinion Piece

  AI and Human Organoids could Redefine Drug Safety before Trials begin

12Next